MARKET

QLGN

QLGN

Qualigen Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.450
-0.110
-2.41%
After Hours: 4.450 0 0.00% 18:14 10/20 EDT
OPEN
4.570
PREV CLOSE
4.560
HIGH
4.600
LOW
4.380
VOLUME
560.13K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
3.710
MARKET CAP
121.31M
P/E (TTM)
-0.4463
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Qualigen Therapeutics announces commercialization agreement for FastPack in China
Qualigen Therapeutics ([[QLGN]] +3.6%) has entered an agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd, of Suzhou, China to develop, manufacture and sell new generations of diagnostic test systems
Seekingalpha · 10/08 13:58
Qualigen Therapeutics Enters into Commercialization Agreement for its FastPack® Diagnostic Products in China
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces it has entered into an agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd, of Suzhou, China to develop, manufacture and sell new generations of diagnostic test systems based on Qualigen's core FastPack® "laboratory in a pouch" technology
PR Newswire · 10/08 13:00
Qualigen expands research pact with UofL for ALAN cancer drug candidate
Qualigen Therapeutics ([[QLGN]] -3.4%) has entered into an amended Sponsored Research Agreement with the University of Louisville (UofL) to advance development of its AS1411-GNP, also known as ALAN (Aptamer-Linked Anti-Nucleolin)
Seekingalpha · 10/01 15:52
Qualigen Therapeutics Reports Expansion Of Research Deal With University Of Louisville For ALAN Cancer Drug Candidate
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announces it has entered into an amended Sponsored Research Agreement with the University of Louisville (UofL) to advance development of Qualigen's anticancer drug candidate
Benzinga · 10/01 13:23
Qualigen Therapeutics Expands Research Agreement with University of Louisville for ALAN Cancer Drug Candidate
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) announces it has entered into an amended Sponsored Research Agreement with the University of Louisville (UofL) to advance development of Qualigen's anticancer drug candidate AS1411-GNP, also known as ALAN (Aptamer-Linked Anti-Nucleolin).
PR Newswire · 10/01 13:00
QLGN: Initiating Coverage of Qualigen Therapeutics, Inc.; Targeting Cancer and Infectious Diseases…
By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT We are initiating coverage of Qualigen Therapeutics, Inc. (NASDAQ:QLGN) with a valuation of $10.00. Qualigen is a biopharmaceutical company developing novel treatments for cancer and infectious diseases while continuing and expanding
Zacks Small Cap Research · 09/21 15:53
Qualigen files U.S. provisional patent application for AS1411
Qualigen Therapeutics ([[QLGN]]) jointly files U.S. provisional patent application with the University of Louisville, entitled "Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent."The patent application
Seekingalpha · 09/17 13:30
Qualigen Therapeutics Announces Filing of U.S. Provisional Patent Application for the Use of AS1411 to Prevent Viral Infections
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces its and the University of Louisville's joint filing of a United States provisional patent application, entitled "Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent." The application
PR Newswire · 09/17 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of QLGN. Analyze the recent business situations of Qualigen Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average QLGN stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 22
Institutional Holdings: 628.56K
% Owned: 2.31%
Shares Outstanding: 27.26M
TypeInstitutionsShares
Increased
3
60.23K
New
9
35.31K
Decreased
2
50
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.90%
Pharmaceuticals & Medical Research
-0.28%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Poirier
Chief Financial Officer/Vice President - Finance
Christopher Lotz
Chief Scientific Officer/Vice President - Research & Development
Wajdi Abdul-Ahad
Vice President - Operations
Shishir Sinha
Director
Ira Ritter
Independent Director
Amy Broidrick
Independent Director
Richard David
Independent Director
Matthew Korenberg
Independent Director
Kurt Kruger
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About QLGN
Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotechnology company. The Company is focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as development of its FastPack diagnostic platform. Its pipeline includes AS1411, Aptamer Linked Anti Nucleolin (ALAN), Aptamer Linked Anti Nucleolin - Contrast Enhancement (ALAN-CE), Aptamer Linked Anti Nucleolin - Radiation Enhancement (ALAN-RE), Selective Target Antigen Removal System (STARS) and RAS-F. The FastPack System is an immunoassay testing system, which consists of the FastPack Analyzer and the FastPack test pouch, a single-use, disposable, foil packet which includes the FastPack reagent chemistry. The Company’s subsidiary is Qualigen, Inc.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Qualigen Therapeutics Inc stock information, including NASDAQ:QLGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QLGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QLGN stock methods without spending real money on the virtual paper trading platform.